More about Moderna’s Prophylactic Vaccines Modality
- Posted by ISPE Boston
- On February 27, 2020
Moderna scientists designed the prophylactic vaccines modality to prevent infectious diseases. More than 1,000 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Based on clinical experience across six Phase 1 studies, the Company has designated prophylactic vaccines a core modality and intends to […]
Read More